Restore Vision
Latest round
- Series A
Last raised
- Dec 2023
Total raised
- $23M
Investors
- 12
About Restore Vision
Based in Tokyo, Japan, and founded in 2016, Restore Vision Inc. specializes in research and development of regenerative medicine. Yusaku Katada (CEO) is the founding scientists of the company. In April 2026, Restore Vision Inc. The company develops a visual restoration gene therapy for retinitis pigmentosa and optical sensor protein (drug) for intractable eye illnesses using its technology. Its chimeric rhodopsin genes overcome the limitations of traditional rhodopsins and keep them working with great sensitivity for patients, aiding in the treatment of eye illnesses.
Who invested in Restore Vision
12 investors across 3 rounds
See all investors in Restore Vision
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Restore Vision
Who invested in Restore Vision?
Restore Vision has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Restore Vision raised?
Restore Vision has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Restore Vision last raise money?
Restore Vision's most recent round on record is a Series A, in Dec 2023.
What does Restore Vision do?
Based in Tokyo, Japan, and founded in 2016, Restore Vision Inc.
Where is Restore Vision headquartered?
Restore Vision is headquartered in Japan.
Which VCs invest in companies like Restore Vision?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Restore Vision's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Restore Vision? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.